Jupiter Asset Management Ltd. Reduces Stake in Intellia Therapeutics, Inc. $NTLA

Jupiter Asset Management Ltd. decreased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 23.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,037,918 shares of the company’s stock after selling 323,931 shares during the period. Jupiter Asset Management Ltd.’s holdings in Intellia Therapeutics were worth $9,331,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after buying an additional 1,965,181 shares in the last quarter. Contrarius Group Holdings Ltd boosted its position in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after acquiring an additional 4,337,428 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Intellia Therapeutics by 2.7% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock worth $47,435,000 after acquiring an additional 71,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after acquiring an additional 107,333 shares during the period. Finally, Two Sigma Investments LP raised its position in shares of Intellia Therapeutics by 7.6% in the 3rd quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock worth $42,305,000 after acquiring an additional 173,033 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada lifted their price target on Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 3rd. Truist Financial upgraded Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. The Goldman Sachs Group boosted their target price on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, April 28th. reaffirmed a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday, March 3rd. Finally, Canaccord Genuity Group decreased their price target on shares of Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Stock Up 2.9%

Intellia Therapeutics stock opened at $14.07 on Friday. Intellia Therapeutics, Inc. has a twelve month low of $6.83 and a twelve month high of $28.25. The company has a market capitalization of $1.97 billion, a P/E ratio of -3.97 and a beta of 1.93. The stock’s 50 day moving average is $13.55 and its 200 day moving average is $12.00.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. During the same quarter in the previous year, the business earned ($1.10) earnings per share. As a group, equities analysts expect that Intellia Therapeutics, Inc. will post -3.29 EPS for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.